Athira Pharma Stock Revenue

ATHA Stock  USD 0.62  0.01  1.59%   
Athira Pharma fundamentals help investors to digest information that contributes to Athira Pharma's financial success or failures. It also enables traders to predict the movement of Athira Stock. The fundamental analysis module provides a way to measure Athira Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Athira Pharma stock.
Last ReportedProjected for Next Year
As of November 26, 2024, Current Deferred Revenue is expected to decline to about (347.8 K). In addition to that, Cost Of Revenue is expected to decline to about 899.2 K.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Athira Pharma Company Revenue Analysis

Athira Pharma's Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.

Revenue

 = 

Money Received

-

Discounts and Returns

More About Revenue | All Equity Analysis

Historical and Projected quarterly revenue of Athira

Projected quarterly revenue analysis of Athira Pharma provides investors and stakeholders with an insight into the company's performance and growth prospects. When actual revenues of Athira Pharma match or exceed analyst estimates, it positively influences investor confidence and market perception, often leading to a rise in Athira Pharma's stock price.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Competition

Based on the latest financial disclosure, Athira Pharma reported 0.0 of revenue. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The revenue for all United States stocks is 100.0% higher than that of the company.

Athira Revenue Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Athira Pharma's direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Athira Pharma could also be used in its relative valuation, which is a method of valuing Athira Pharma by comparing valuation metrics of similar companies.
Athira Pharma is currently under evaluation in revenue category among its peers.

Athira Pharma Institutional Holders

Institutional Holdings refers to the ownership stake in Athira Pharma that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Athira Pharma's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Athira Pharma's value.
Shares
Dimensional Fund Advisors, Inc.2024-09-30
321.4 K
Geode Capital Management, Llc2024-09-30
320.8 K
Two Sigma Investments Llc2024-09-30
258.5 K
Bank Of America Corp2024-06-30
228.7 K
Laird Norton Tyee Trust Co2024-09-30
147.3 K
State Street Corp2024-06-30
107.8 K
Barclays Plc2024-06-30
103.1 K
Bridgeway Capital Management, Llc2024-09-30
88.9 K
Susquehanna International Group, Llp2024-06-30
61.8 K
Perceptive Advisors Llc2024-09-30
5.4 M
Vanguard Group Inc2024-09-30
1.6 M

Athira Fundamentals

About Athira Pharma Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Athira Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Athira Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Athira Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Athira Pharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Athira Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Athira Pharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Athira Pharma Stock:
Check out Athira Pharma Piotroski F Score and Athira Pharma Altman Z Score analysis.
For information on how to trade Athira Stock refer to our How to Trade Athira Stock guide.
You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Athira Pharma. If investors know Athira will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Athira Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.78)
Return On Assets
(0.48)
Return On Equity
(0.85)
The market value of Athira Pharma is measured differently than its book value, which is the value of Athira that is recorded on the company's balance sheet. Investors also form their own opinion of Athira Pharma's value that differs from its market value or its book value, called intrinsic value, which is Athira Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Athira Pharma's market value can be influenced by many factors that don't directly affect Athira Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Athira Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Athira Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Athira Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.